Table 2.
Cost-effectiveness Results of Hepatitis C Virus Antenatal Versus Background Screening
| Scenario | Cost Per Person, in 2018 USD Mean (2.5–97.5% Intervals) |
QALYs Per Person Mean (2.5–97.5% Intervals) |
Incremental Cost Per Person Mean (2.5–97.5% Intervals) |
Incremental QALYs Per Person Mean (2.5–97.5% Intervals) |
Mean ICER USD/QALY Gained |
|---|---|---|---|---|---|
| Background screening | 921 (443–1397) |
25.312 (25.297–25.325) |
… | … | … |
| Universal antenatal screening and treatment after pregnancy, regardless of fibrosis stage | 975 (442–1510) |
25.331 (25.315–25.343) |
53 (−102–175) |
0.019 (0.010–0.028) |
2826 |
Abbreviations: ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life-years; USD, United States dollars.